Welcome to our dedicated page for QHSLab SEC filings (Ticker: USAQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QHSLab, Inc. (OTCQB: USAQ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports. QHSLab is a Nevada corporation with common stock registered under Section 12(g) of the Securities Exchange Act of 1934, and it uses these filings to report on its digital health and medical device business focused on primary care screening, assessments, and point-of-care diagnostics.
For investors analyzing USAQ, the company’s periodic reports detail revenue contributions from Integrated Service Program services, allergy diagnostic kits, immunotherapy, clinical study revenue, subscriptions, and related categories. These filings also discuss gross margin trends, operating performance, and risk factors relevant to a healthcare technology and medical devices issuer. Annual Form 10-K and quarterly Form 10-Q documents are key sources for understanding QHSLab’s business model, segment mix, and cash flow profile.
QHSLab’s Form 8-K current reports provide additional insight into material events. Recent 8-Ks describe a note repurchase agreement that extinguished defaulted convertible promissory notes, a promissory note modification and partial conversion, and a private placement of common stock and warrants to accredited investors. Other 8-Ks furnish press releases about product launches such as the Q-Cog™ cognitive assessment, corporate presentations, shareholder letters, and financial and operational updates.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight the most important points in each document. Users can quickly see what changed in a new 10-Q, how a financing or debt restructuring described in an 8-K affects capital structure, and where to find details on revenue composition, digital health initiatives, and risk disclosures. Form 4 insider transaction reports, when filed, can also be reviewed to track equity activity by QHSLab officers, directors, or significant shareholders.
QHSLab, Inc. (USAQ) filed an 8-K to furnish a shareholder letter under Regulation FD. On November 24, 2025, the company reported that it sent a letter to its shareholders, which is attached as Exhibit 99.1. The information in this exhibit is furnished under Item 7.01, meaning it is not considered “filed” for liability purposes under Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
The company reiterates that it has no obligation to update forward-looking statements. It also highlights that investors, media, and others may receive material information through its website (usaqcorp.com), press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) entered into a Note Repurchase Agreement on November 18, 2025 to buy back its outstanding defaulted convertible promissory notes. These notes, issued in 2021 and 2022, had an aggregate outstanding balance of principal and accrued interest in excess of
QHSLab, Inc. reported Q3 2025 results. Revenue was $737,066, up from $544,285 a year ago, with gross profit of $493,631 and a steady gross margin of 67.0%. Quarterly net income was $33,411, while for the nine months year‑to‑date the company recorded a net loss of $99,156 on revenue of $1,987,931 and gross margin of 66.5%.
Operating expenses rose to support growth, led by higher sales and marketing and increased R&D tied to the QHSLab platform. Cash was $158,391 as of September 30, 2025, against total current liabilities of $2,345,536. Accounts receivable, net, were $210,131.
The company disclosed substantial doubt about its ability to continue as a going concern. It is in default on an acquisition promissory note with $461,127 of principal and accrued interest outstanding, and received default notices on two OID convertible notes with remaining principal balances of $646,841 and $462,306; default interest is accruing at 18%. On November 13, 2025, shares outstanding were 11,281,527. Management notes continued efforts to grow Integrated Service Program revenues and to discuss note terms with the current holder.